表紙
市場調查報告書
商品編碼
1069202

全球藥物發現市場預測(2022-2030)

Global Drug Discovery Market Forecast 2022-2030

出版日期: | 出版商: Inkwood Research | 英文 235 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

預計 2022 年至 2030 年期間,全球藥物發現市場將以 6.58% 的複合年增長率增長。推動市場增長的關鍵因素包括增加治療每種疾病的研發和技術進步。

從區域上看,歐洲和北美國家幾十年來一直在引領藥物發現,這主要歸功於宣傳計劃、政府和 CRO 的努力、製藥公司等。然而,項目可行性和成功率、高度監管的市場以及耗時的流程正在阻礙市場增長。

本報告調查全球藥物發現市場,並提供有關市場規模和預測、市場動態、按細分市場/地區的市場分析、市場份額、競爭條件和戰略、主要公司概況等信息。

目錄

第一章調查範圍及調查方法

  • 調查目的
  • 調查範圍
  • 調查方法
  • 先決條件和限制

第2章執行摘要

  • 市場規模/估計
  • 市場概況

第三章市場動態

  • 主要促進者
    • 應對各種疾病的研發增長
    • 技術進步
  • 主要製約因素
    • 一個巨大的耗時過程
    • 高度監管的市場
    • 項目可行性和成功率

第4章關鍵分析

  • COVID-19 對市場的影響
  • 主要市場趨勢
  • 波特五力分析
  • 市場機會矩陣
  • 藥物發現和開發過程
  • 監管框架

第 5 章按藥物類型劃分的市場

  • 小分子藥物
  • 生物製劑

第 6 章按服務劃分的市場

  • 化工服務
  • 藥物代謝/藥代動力學服務
  • 生物服務
  • 其他

第 7 章最終用戶市場

  • 製藥公司
  • 合同研究機構
  • 研究所
  • 其他

第 8 章技術市場

  • 高通量篩選
  • 光譜學
  • 組合化學
  • 生物芯片
  • 藥物基因組學和藥物遺傳學
  • 生物信息學
  • 代謝組學
  • 納米技術
  • 其他

第9章區域分析

  • 北美
  • 歐洲
  • 亞太地區
  • 其他領域

第10章競爭態勢

  • 主要戰略發展
    • 併購
    • 產品發布和開發
    • 合作夥伴關係和合同
    • 業務拓展及銷售
  • 公司簡介
    • AGILENT TECHNOLOGIES INC
    • ASTRAZENECA PLC
    • BAYER AG
    • CHARLES RIVER LABORATORIES INTERNATIONAL INC
    • ELI LILLY AND COMPANY
    • EVOTEC SE
    • GLAXOSMITHKLINE PLC
    • ICON PLC
    • IQVIA HOLDINGS INC
    • JOHNSON & JOHNSON
    • MERCK & CO INC
    • NOVARTIS AG
    • PFIZER INC
    • ROCHE AG
目錄
Product Code: 13150

KEY FINDINGS

The global drug discovery market is projected to register a CAGR of 6.58% during the forecast period, 2022-2030. The increasing R&D efforts for multiple diseases cure and the technological advancements are the primary factors propelling the market growth.

MARKET INSIGHTS

Drug discovery entails identifying the potential new medicines in a vast range of scientific disciplines like pharmacology, chemistry, and biology. The drug discovery process landscape has witnessed radical changes with innovative methods and technologies for drug development. This has enabled research organizations and pharmaceutical companies to find solutions and cures for several diseases and health conditions. In addition, companies are introducing nanotechnology, biochips, automated processes, cloud computing, and artificial intelligence.

At the same time, the process of new drug discovery and development needs almost 10-15 years, encompassing preliminary research to introducing drugs to the market. Also, there are risks associated with any development phase that must be considered.

Geographically, the European and North American countries have excelled for decades in drug discovery, majorly attributed to awareness programs, government & CRO initiatives, pharmaceutical companies, etc. The market growth restraining factors include project feasibility & success rate, highly regulated market, and time-consuming process.

REGIONAL INSIGHTS

The global drug discovery market growth analysis includes the geographical assessment of North America, Europe, Asia-Pacific, and Rest of World. North America is the leading region with regard to the highest revenue share, mostly attributed to advancements in various technologies.

COMPETITIVE INSIGHTS

The intense competitive rivalry is due to the collaborations, partnerships, and fund projects among new market players. Some of the leading companies in the market include Roche AG, Eli Lilly and Company, Johnson & Johnson, Novartis AG, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. KEY DRIVERS
    • 3.1.1. GROWING R&D FOR TACKLING SEVERAL DISEASES
    • 3.1.2. TECHNOLOGICAL ADVANCEMENTS
  • 3.2. KEY RESTRAINTS
    • 3.2.1. EXTENSIVE TIME-CONSUMING PROCESS
    • 3.2.2. HIGHLY REGULATED MARKET
    • 3.2.3. PROJECT FEASIBILITY AND SUCCESS RATE

4. KEY ANALYTICS

  • 4.1. IMPACT OF COVID-19 ON GLOBAL DRUG DISCOVERY MARKET
  • 4.2. KEY MARKET TRENDS
  • 4.3. PORTER'S FIVE FORCES ANALYSIS
    • 4.3.1. BUYERS POWER
    • 4.3.2. SUPPLIERS POWER
    • 4.3.3. SUBSTITUTION
    • 4.3.4. NEW ENTRANTS
    • 4.3.5. INDUSTRY RIVALRY
  • 4.4. OPPORTUNITY MATRIX
  • 4.5. DRUG DISCOVERY AND DEVELOPMENT PROCESS
    • 4.5.1. DRUG DISCOVERY AND DEVELOPMENT
    • 4.5.2. PRECLINICAL RESEARCH
    • 4.5.3. CLINICAL RESEARCH
    • 4.5.4. REGULATORY AUTHORITY REVIEW
    • 4.5.5. POST MARKET SAFETY MONITORING
  • 4.6. REGULATORY FRAMEWORK

5. MARKET BY DRUG TYPE

  • 5.1. SMALL MOLECULE DRUG
  • 5.2. BIOLOGIC DRUG

6. MARKET BY SERVICE

  • 6.1. CHEMICAL SERVICES
  • 6.2. DRUG METABOLISM AND PHARMACOKINETICS SERVICES
  • 6.3. BIOLOGICAL SERVICES
  • 6.4. OTHER PHARMACEUTICAL SERVICES

7. MARKET BY END-USERS

  • 7.1. PHARMACEUTICAL COMPANIES
  • 7.2. CONTRACT RESEARCH ORGANIZATIONS
  • 7.3. RESEARCH INSTITUTES
  • 7.4. OTHER END-USERS

8. MARKET BY TECHNOLOGY

  • 8.1. HIGH THROUGHPUT SCREENING
  • 8.2. SPECTROSCOPY
  • 8.3. COMBINATORIAL CHEMISTRY
  • 8.4. BIOCHIPS
  • 8.5. PHARMACOGENOMICS AND PHARMACOGENETICS
  • 8.6. BIOINFORMATICS
  • 8.7. METABOLOMICS
  • 8.8. NANOTECHNOLOGY
  • 8.9. OTHER TECHNOLOGIES

9. GEOGRAPHICAL ANALYSIS

  • 9.1. NORTH AMERICA
    • 9.1.1. MARKET SIZE & ESTIMATES
    • 9.1.2. KEY GROWTH ENABLERS
    • 9.1.3. KEY CHALLENGES
    • 9.1.4. KEY PLAYERS
    • 9.1.5. COUNTRY ANALYSIS
      • 9.1.5.1. UNITED STATES
      • 9.1.5.2. CANADA
  • 9.2. EUROPE
    • 9.2.1. MARKET SIZE & ESTIMATES
    • 9.2.2. KEY GROWTH ENABLERS
    • 9.2.3. KEY CHALLENGES
    • 9.2.4. KEY PLAYERS
    • 9.2.5. COUNTRY ANALYSIS
      • 9.2.5.1. UNITED KINGDOM
      • 9.2.5.2. GERMANY
      • 9.2.5.3. FRANCE
      • 9.2.5.4. ITALY
      • 9.2.5.5. RUSSIA
      • 9.2.5.6. SPAIN
      • 9.2.5.7. SCANDINAVIA
      • 9.2.5.8. REST OF EUROPE
  • 9.3. ASIA-PACIFIC
    • 9.3.1. MARKET SIZE & ESTIMATES
    • 9.3.2. KEY GROWTH ENABLERS
    • 9.3.3. KEY CHALLENGES
    • 9.3.4. KEY PLAYERS
    • 9.3.5. COUNTRY ANALYSIS
      • 9.3.5.1. CHINA
      • 9.3.5.2. JAPAN
      • 9.3.5.3. INDIA
      • 9.3.5.4. SOUTH KOREA
      • 9.3.5.5. INDONESIA
      • 9.3.5.6. SINGAPORE
      • 9.3.5.7. TAIWAN
      • 9.3.5.8. AUSTRALIA & NEW ZEALAND
      • 9.3.5.9. REST OF ASIA-PACIFIC
  • 9.4. REST OF WORLD
    • 9.4.1. MARKET SIZE & ESTIMATES
    • 9.4.2. KEY GROWTH ENABLERS
    • 9.4.3. KEY CHALLENGES
    • 9.4.4. KEY PLAYERS
    • 9.4.5. REGIONAL ANALYSIS
      • 9.4.5.1. LATIN AMERICA
      • 9.4.5.2. MIDDLE EAST & AFRICA

10. COMPETITIVE LANDSCAPE

  • 10.1. KEY STRATEGIC DEVELOPMENTS
    • 10.1.1. MERGERS & ACQUISITIONS
    • 10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
    • 10.1.3. PARTNERSHIPS & AGREEMENTS
    • 10.1.4. BUSINESS EXPANSIONS & DIVESTITURES
  • 10.2. COMPANY PROFILES
    • 10.2.1. AGILENT TECHNOLOGIES INC
    • 10.2.2. ASTRAZENECA PLC
    • 10.2.3. BAYER AG
    • 10.2.4. CHARLES RIVER LABORATORIES INTERNATIONAL INC
    • 10.2.5. ELI LILLY AND COMPANY
    • 10.2.6. EVOTEC SE
    • 10.2.7. GLAXOSMITHKLINE PLC
    • 10.2.8. ICON PLC
    • 10.2.9. IQVIA HOLDINGS INC
    • 10.2.10. JOHNSON & JOHNSON
    • 10.2.11. MERCK & CO INC
    • 10.2.12. NOVARTIS AG
    • 10.2.13. PFIZER INC
    • 10.2.14. ROCHE AG

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - GLOBAL DRUG DISCOVERY
  • TABLE 2: REGULATORY FRAMEWORK
  • TABLE 3: GLOBAL DRUG DISCOVERY MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 4: GLOBAL DRUG DISCOVERY MARKET, BY DRUG TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 5: GLOBAL SMALL MOLECULE DRUG MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 6: GLOBAL SMALL MOLECULE DRUG MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 7: GLOBAL BIOLOGIC DRUG MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 8: GLOBAL BIOLOGIC DRUG MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 9: GLOBAL DRUG DISCOVERY MARKET, BY SERVICE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 10: GLOBAL DRUG DISCOVERY MARKET, BY SERVICE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 11: GLOBAL CHEMICAL SERVICES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 12: GLOBAL CHEMICAL SERVICES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 13: GLOBAL DRUG METABOLISM AND PHARMACOKINETICS SERVICES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 14: GLOBAL DRUG METABOLISM AND PHARMACOKINETICS SERVICES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 15: GLOBAL BIOLOGICAL SERVICES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 16: GLOBAL BIOLOGICAL SERVICES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 17: GLOBAL OTHER PHARMACEUTICAL SERVICES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 18: GLOBAL OTHER PHARMACEUTICAL SERVICES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 19: GLOBAL DRUG DISCOVERY MARKET, BY END-USERS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 20: GLOBAL DRUG DISCOVERY MARKET, BY END-USERS, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 21: GLOBAL PHARMACEUTICAL COMPANIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 22: GLOBAL PHARMACEUTICAL COMPANIES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 23: GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 24: GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 25: GLOBAL RESEARCH INSTITUTES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 26: GLOBAL RESEARCH INSTITUTES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 27: GLOBAL OTHER END-USERS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 28: GLOBAL OTHER END-USERS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 29: GLOBAL DRUG DISCOVERY MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 30: GLOBAL DRUG DISCOVERY MARKET, BY TECHNOLOGY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 31: GLOBAL HIGH THROUGHPUT SCREENING MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 32: GLOBAL HIGH THROUGHPUT SCREENING MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 33: GLOBAL SPECTROSCOPY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 34: GLOBAL SPECTROSCOPY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 35: GLOBAL COMBINATORIAL CHEMISTRY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 36: GLOBAL COMBINATORIAL CHEMISTRY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 37: GLOBAL BIOCHIPS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 38: GLOBAL BIOCHIPS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 39: GLOBAL PHARMACOGENOMICS AND PHARMACOGENETICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 40: GLOBAL PHARMACOGENOMICS AND PHARMACOGENETICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 41: GLOBAL BIOINFORMATICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 42: GLOBAL BIOINFORMATICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 43: GLOBAL METABOLOMICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 44: GLOBAL METABOLOMICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 45: GLOBAL NANOTECHNOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 46: GLOBAL NANOTECHNOLOGY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 47: GLOBAL OTHER TECHNOLOGIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 48: GLOBAL OTHER TECHNOLOGIES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 49: GLOBAL DRUG DISCOVERY MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 50: GLOBAL DRUG DISCOVERY MARKET, BY GEOGRAPHY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 51: NORTH AMERICA DRUG DISCOVERY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 52: NORTH AMERICA DRUG DISCOVERY MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 53: LEADING PLAYERS OPERATING IN NORTH AMERICA DRUG DISCOVERY MARKET
  • TABLE 54: EUROPE DRUG DISCOVERY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 55: EUROPE DRUG DISCOVERY MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 56: LEADING PLAYERS OPERATING IN EUROPE DRUG DISCOVERY MARKET
  • TABLE 57: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 58: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 59: LEADING PLAYERS OPERATING IN ASIA-PACIFIC DRUG DISCOVERY MARKET
  • TABLE 60: REST OF WORLD DRUG DISCOVERY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 61: REST OF WORLD DRUG DISCOVERY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 62: LEADING PLAYERS OPERATING IN REST OF WORLD DRUG DISCOVERY MARKET
  • TABLE 63: LIST OF MERGERS & ACQUISITIONS
  • TABLE 64: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
  • TABLE 65: LIST OF PARTNERSHIPS & AGREEMENTS
  • TABLE 66: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES

  • FIGURE 1: KEY MARKET TRENDS
  • FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 3: OPPORTUNITY MATRIX
  • FIGURE 4: DRUG DISCOVERY AND DEVELOPMENT PROCESS
  • FIGURE 5: GLOBAL DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2021
  • FIGURE 6: GLOBAL DRUG DISCOVERY MARKET, BY SMALL MOLECULE DRUG, 2022-2030 (IN $ MILLION)
  • FIGURE 7: GLOBAL DRUG DISCOVERY MARKET, BY BIOLOGIC DRUG, 2022-2030 (IN $ MILLION)
  • FIGURE 8: GLOBAL DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY SERVICE, IN 2021
  • FIGURE 9: GLOBAL DRUG DISCOVERY MARKET, BY CHEMICAL SERVICES, 2022-2030 (IN $ MILLION)
  • FIGURE 10: GLOBAL DRUG DISCOVERY MARKET, BY DRUG METABOLISM AND PHARMACOKINETICS SERVICES, 2022-2030 (IN $ MILLION)
  • FIGURE 11: GLOBAL DRUG DISCOVERY MARKET, BY BIOLOGICAL SERVICES, 2022-2030 (IN $ MILLION)
  • FIGURE 12: GLOBAL DRUG DISCOVERY MARKET, BY OTHER PHARMACEUTICAL SERVICES, 2022-2030 (IN $ MILLION)
  • FIGURE 13: GLOBAL DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY END-USERS, IN 2021
  • FIGURE 14: GLOBAL DRUG DISCOVERY MARKET, BY PHARMACEUTICAL COMPANIES, 2022-2030 (IN $ MILLION)
  • FIGURE 15: GLOBAL DRUG DISCOVERY MARKET, BY CONTRACT RESEARCH ORGANIZATIONS, 2022-2030 (IN $ MILLION)
  • FIGURE 16: GLOBAL DRUG DISCOVERY MARKET, BY RESEARCH INSTITUTES, 2022-2030 (IN $ MILLION)
  • FIGURE 17: GLOBAL DRUG DISCOVERY MARKET, BY OTHER END-USERS, 2022-2030 (IN $ MILLION)
  • FIGURE 18: GLOBAL DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2021
  • FIGURE 19: GLOBAL DRUG DISCOVERY MARKET, BY HIGH THROUGHPUT SCREENING, 2022-2030 (IN $ MILLION)
  • FIGURE 20: GLOBAL DRUG DISCOVERY MARKET, BY SPECTROSCOPY, 2022-2030 (IN $ MILLION)
  • FIGURE 21: GLOBAL DRUG DISCOVERY MARKET, BY COMBINATORIAL CHEMISTRY, 2022-2030 (IN $ MILLION)
  • FIGURE 22: GLOBAL DRUG DISCOVERY MARKET, BY BIOCHIPS, 2022-2030 (IN $ MILLION)
  • FIGURE 23: GLOBAL DRUG DISCOVERY MARKET, BY PHARMACOGENOMICS AND PHARMACOGENETICS, 2022-2030 (IN $ MILLION)
  • FIGURE 24: GLOBAL DRUG DISCOVERY MARKET, BY BIOINFORMATICS, 2022-2030 (IN $ MILLION)
  • FIGURE 25: GLOBAL DRUG DISCOVERY MARKET, BY METABOLOMICS, 2022-2030 (IN $ MILLION)
  • FIGURE 26: GLOBAL DRUG DISCOVERY MARKET, BY NANOTECHNOLOGY, 2022-2030 (IN $ MILLION)
  • FIGURE 27: GLOBAL DRUG DISCOVERY MARKET, BY OTHER TECHNOLOGIES, 2022-2030 (IN $ MILLION)
  • FIGURE 28: NORTH AMERICA DRUG DISCOVERY MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
  • FIGURE 29: UNITED STATES DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 30: CANADA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 31: EUROPE DRUG DISCOVERY MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
  • FIGURE 32: UNITED KINGDOM DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 33: GERMANY DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 34: FRANCE DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 35: ITALY DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 36: RUSSIA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 37: SPAIN DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 38: SCANDINAVIA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 39: REST OF EUROPE DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 40: ASIA-PACIFIC DRUG DISCOVERY MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
  • FIGURE 41: CHINA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 42: JAPAN DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 43: INDIA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 44: SOUTH KOREA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 45: INDONESIA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 46: SINGAPORE DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 47: TAIWAN DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 48: AUSTRALIA & NEW ZEALAND DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 49: REST OF ASIA-PACIFIC DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 50: REST OF WORLD DRUG DISCOVERY MARKET, REGIONAL OUTLOOK, 2021 & 2030 (IN %)
  • FIGURE 51: LATIN AMERICA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 52: MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)